A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
A phase 1/2 trial of GC012F in multiple myeloma, run by Gracell Biotechnologies (Shanghai) Co., Ltd., now recruiting.
Overview
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06235229 by Gracell Biotechnologies (Shanghai) Co., Ltd., with 110 participants planned, started 2023-12-26 and due to reach its primary completion in 2026-03-02. Interventions recorded: GC012F. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Setting
A Phase I/II Clinical Study of Chimeric Antigen Receptor T-cell Therapy Targeting CD19 and BCMA (GC012F) in Patients With Relapsed/Refractory Multiple Myeloma
Phase
Phase 1/2
Sponsor
Gracell Biotechnologies (Shanghai) Co., Ltd.
Registry
Enrolled
110